Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026
Apyx Medical (APYX) will release its third-quarter fiscal 2026 financial results before markets open on November 5, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Apyx Medical (APYX) will release its third-quarter fiscal 2026 financial results before markets open on November 5, 2026. Management will discuss the results on a conference call at 8:00 a.m. Eastern Time that day, followed by a question-and-answer session. A live webcast will be available through the company’s Investor Relations website and archived for future reference.
Details
Market move: APYX -5.98% vs previous close. 3Q26 earnings date
On Oct 22, the day this news came out, the latest delayed price for APYX is 5.98% below the previous close. Our momentum scanner has recorded 8 alerts for this stock so far that day. The latest delayed price is $2.36. Relative volume is elevated at 2.1x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Scheduled results release
- November 5, 2026
- Third-quarter fiscal 2026 financial results; before markets open
AI-generated analysis. How Rhea-AI works. Not financial advice.
CLEARWATER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the third quarter of fiscal year 2026 will be released before markets open on Thursday, November 5th.
Management will host a conference call at 8:00 a.m. Eastern Time on Thursday, November 5th, to discuss the results of the quarter, followed by a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 20167. Participants should ask for the “Apyx Medical Corporation Call”. A live webcast of the call will be accessible via the following link: Apyx Medical Earnings Webcast and via the Investor Relations section of the Company’s website, where it will also be archived for future reference.
About Apyx Medical Corporation:
Apyx Medical Corporation is a surgical aesthetics company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion® and the AYON Body Contouring System™ in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 100 clinical documents. The AYON Body Contouring System is an FDA-cleared, groundbreaking, surgeon-designed body contouring system that combines precision, versatility, and innovation in an all-in-one platform. It seamlessly integrates fat removal, closed loop contouring, electrosurgical capabilities and Renuvion for tissue contraction, empowering surgeons to deliver the most comprehensive body contouring treatments for patients. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.
Investor Relations Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
OP: 212-915-2568
jfeffer@lifesciadvisors.com
